AVEO Pharmaceuticals is a biopharmaceutical company that provides a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company develops Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced renal cell carcinoma. It offers therapies for cancer using proprietary genetic model systems that enable the identification of essential targets critical to the origin, maintenance and spread of malignant tumors.